Progress in immunotherapy of bladder cancer

doi:10.3877/cma.j.issn.1674-0785.2025.06.012

Abstract

Abstract:

Bladder cancer is a common malignant tumor of the urinary system, and immunotherapy has brought new opportunities for its treatment. This article synthesizes the relevant literature to elaborate on various methods of immunotherapy for bladder cancer, including immune checkpoint inhibitor therapy and bacille Calmette-Guérin (BCG) intravesical perfusion therapy. By analyzing their curative effects, related biomarkers, and safety profiles, this paper discusses the challenges faced by immunotherapy and its future development directions, aiming to provide a comprehensive reference for immunotherapy of bladder cancer and promote advancements in clinical practice.

Key words: Bladder cancer, Immunotherapy, Immune checkpoint inhibitors, BCG, Biomarkers

Yuhan Hou, Fujin Jiang, Sugui Wang. Progress in immunotherapy of bladder cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(06): 471-475.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2025.06.012

https://zhlcyszz.cma-cmc.com.cn/EN/Y2025/V19/I06/471

References 40

1	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263.
2	Dyrskjøt L, Hansel DE, Efstathiou JA, et al. Bladder cancer [J]. Nat Rev Dis Primers, 2023, 9(1): 58.
3	Lenis AT, Lec PM, Chamie K, et al. Bladder Cancer: a review [J]. JAMA, 2020, 324(19): 1980-1991.
4	Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape [J]. Nat Immunol, 2002, 3(11): 991-998.
5	Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy [J]. Science, 2020, 367(6477): eaax0182.
6	Han J, Gu X, Li Y, et al. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect [J]. Biomed Pharmacother, 2020, 129: 110393.
7	Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience [J]. Eur Urol, 2017, 71(6): 952-960.
8	Chu C, Pietzak E. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue "Seminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma" [J]. Urol Oncol, 2023, 41(10): 398-409.
9	Kraehenbuehl L, Weng CH, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways [J]. Nat Rev Clin Oncol, 2022, 19(1): 37-50.
10	Duan T, Du Y, Xing C, et al. Toll-like receptor signaling and its role in cell-mediated immunity [J]. Front Immunol, 2022, 13: 812774.
11	Hannouneh ZA, Hijazi A, Alsaleem AA, et al. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer [J]. Cancer Med, 2023, 12(24): 21944-21968.
12	Fukushima H, Takao S, Furusawa A, et al. Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer [J]. Cancer Lett, 2024, 585: 216606.
13	Kiss B, van den Berg NS, Ertsey R, et al. CD47-targeted near-infrared photoimmunotherapy for human bladder cancer [J]. Clin Cancer Res, 2019, 25(12): 3561-3571.
14	Siddiqui MR, Railkar R, Sanford T, et al. Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) expressing bladder cancer using combination photoimmunotherapy (PIT) [J]. Sci Rep, 2019, 9(1): 2084.
15	Zhang Z, Li D, Yun H, et al. CAR-T cells in the treatment of urologic neoplasms: present and future [J]. Front Oncol, 2022, 12: 915171.
16	Parriott G, Deal K, Crean S, et al. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer [J]. Immunology, 2020, 160(3): 280-294.
17	Ding M, Lin J, Qin C, et al. Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer [J]. Adv Sci (Weinh), 2024, 11(40): e2400156.
18	MacKay M, Afshinnekoo E, Rub J, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors [J]. Nat Biotechnol, 2020, 38(2): 233-244.
19	Khattak AA, Javed A, Pokhrel P, et al. Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG [J]. Ann Med Surg (Lond), 2025, 87(2): 457-459.
20	Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines [J]. Eur Urol, 2021, 79(1): 82-104.
21	Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study [J]. J Clin Oncol, 2018, 36(34): 3353-3360.
22	Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial [J]. Nat Med, 2019, 25(11): 1706-1714.
23	Galsky MD, Daneshmand S, Izadmehr S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial [J]. Nat Med, 2023, 29(11): 2825-2834.
24	Black PC, Tangen CM, Singh P, et al. Phase 2 trial of atezolizumab in bacillus calmette-guérin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605 [J]. Eur Urol, 2023, 84(6): 536-544.
25	Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, et al. Trophy-U-01, a phase Ⅱ open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes [J]. Ann Oncol, 2024, 35(4): 392-401.
26	Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer [J]. N Engl J Med, 2024, 390(10): 875-888.
27	Galsky MD, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from checkmate 274 [J]. J Clin Oncol, 2025, 43(1): 15-21.
28	Dentro SC, Leshchiner I, Haase K, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes [J]. Cell, 2021, 184(8): 2239-2254.e39.
29	Kang HW, Kim WJ, Choi W, et al. Tumor heterogeneity in muscle-invasive bladder cancer [J]. Transl Androl Urol, 2020, 9(6): 2866-2880.
30	da Costa JB, Gibb EA, Nykopp TK, et al. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy [J]. Urol Oncol, 2022, 40(7): 287-294.
31	Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy [J]. Curr Oncol, 2022, 29(5): 3044-3060.
32	辇伟奇, 聂勇战, 应建明, 等. 肿瘤突变负荷检测及临床应用中国专家共识(2020年版) [J]. 中国癌症防治杂志, 2020, 12(5): 485-494.
33	Jiang T, Chen X, Su C, et al. Pan-cancer analysis of Aridia alterations as biomarkers for immunotherapy outcomes [J]. J Cancer, 2020, 11(4): 776-780.
34	Wang D, Elenbaas B, Murugesan K, et al. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays [J]. NPJ Precis Oncol, 2023, 7(1): 103.
35	Zhou X, Qiu S, Nie L, et al. Classification of muscle-invasive bladder cancer based on immunogenomic profiling [J]. Front Oncol, 2020, 10: 1429.
36	Bai Y, Wu X, Weng M, et al. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features [J]. Indian J Pathol Microbiol, 2023, 66(4): 702-707.
37	Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J]. Genome Med, 2017, 9(1): 34.
38	Russo GI, Musso N, Lo Giudice A, et al. PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer [J]. J Cancer Res Clin Oncol, 2023, 149(7): 3681-3690.
39	Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors [J]. Nat Rev Clin Oncol, 2021, 18(6): 345-362.
40	Lu Y, Yuan X, Wang M, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies [J]. J Hematol Oncol, 2022, 15(1): 47.

[1]	Bobo Chen, Guanqiao Wang, Hongyu Wang, Jianye Hou, Ye Tian. Correlation study between bone metabolic markers and the Outerbridge classification of articular cartilage injuries [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2025, 19(04): 418-426.
[2]	Xiaoxin Duan, Sizhuo Wang, Long Chen, Shengli Dong. Research progress of tumor abnormal proteins in gastrointestinal malignancies [J]. Chinese Archives of General Surgery(Electronic Edition), 2025, 19(05): 356-360.
[3]	Sijun Wang, Qiong Wang, Keyu Li, Xinpu Yuan, Shuomin Zhang, Rui Ma, Tianyu Xie, Chaojun Zhang. Analysis of clinical efficacy of proximal gastrectomy after neoadjuvant chemotherapy combined with immunotherapy for upper gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(06): 637-641.
[4]	Feng Gao, Shaolong Hao, Hao Sun, Wei Han. Research progress of tertiary lymphoid structures in pancreatic cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(05): 570-573.
[5]	Wei Zhang, Yuntao Li, Peizhong Shang, Zhifang Jia, Wei Zhang, Weilin Guo. A case report of laparoscopic radical resection for metastatic gallbladder cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(05): 589-590.
[6]	Xia An, Yusheng Shi, Zhixin Song. Analysis of laboratory detection strategies and clinical value for early screening of colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(04): 446-448.
[7]	Chenhao Zhao, Xudong Zhang, Junmo Yang, He Zhou. Research progress on the predictive efficacy of serum tumor markers for postoperative recurrence in patients with colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(04): 467-470.
[8]	Qiwei Yu, Xingbo Wang, Linya Yao, Xi Zhang, Yufan Wu, Xueming Zeng, Qingqi Zeng. Efficacy of percutaneous tibial nerve stimulation combined with solifenacin in treating bladder dysfunction after radical prostatectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(05): 586-592.
[9]	Xinhong Zhang, Yurong Ma, Zhilei Qiu, Jinli Li, Qian Wang, Haijing Dong. Latent profile analysis of social alienation in bladder cancer patients with urostomy [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(05): 639-644.
[10]	Peng Teng, Jingchang Tian, Chunxiang E, Yang Xiang, Boyu Tian. Development and validation of a prognostic nomogram model for patients with muscle-invasive bladder cancer after radical cystectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(05): 645-652.
[11]	Zhicheng Liao, Li Zhu, Zhiyu Zeng. Multidisciplinary consultation on difficult cases in Guangdong Urological Association (Phase 27): advanced renal cell carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(05): 669-676.
[12]	Bo Li, Wei Zhai, Junhua Zheng. Value of CD70 in accurate diagnosis and treatment of renal cell carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(04): 399-403.
[13]	Xingbao Fang, Guolian Pang, Yuehong Li, Yan Cai. Multiomics-based analysis of expression of MCAM in hepatocellular carcinoma and its relationship with survival prognosis and immune cell infiltration [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 716-724.
[14]	Mingyu Hu, Jingdong Li, Yuzhu Xiao, Jie Huang. Clinical efficacy of sequential surgery after conversion therapy for patients with initially unresectable hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 754-760.
[15]	Fangzheng He, Tao Wu, Changsheng Liao, Xiyong Li, Mengxuan Niu, Pengfei Han. MicroRNA signature omics study in the blood of rats with post-traumatic osteoarthritis model [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2025, 11(05): 257-270.

Please choose a citation manager

Content to export